Galapagos
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies
Galapagos NV reported strong Q3 financials with EUR 3.3 billion in cash, advancing 15+ programs, and preparing for multiple IND applications. Key achievements include FDA IND clearance for GLPG5101, U.S. patient recruitment for Phase II ATALANTA study, and strategic collaborations expanding cell therapy manufacturing. The company plans to submit an IND for GLPG5201 in early 2025 and is confident in its CAR-T data, despite a competitive market. Next financial results call is scheduled for February 13, 2024.
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
Galapagos NV appoints Oleg Nodelman as Non-Executive Non-Independent Director, effective October 7, 2024, replacing Dan G. Baker. Nodelman, Founder and Portfolio Manager of EcoR1 Capital LLC, brings expertise in biotech and shareholder value, aligning with Galapagos' strategy to accelerate innovation and create value.
© Copyright 2025. All Rights Reserved by MedPath